Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Read more
Sign In
May 27, 20216:38 AM PDTLast Updated 2 months ago
Healthcare & Pharmaceuticals
Explainer: How worried should we be about blood clots linked to AstraZeneca, J&J vaccines?
John Miller

7 minute read
Syringes are prepared to administer the AstraZeneca coronavirus disease (COVID-19) vaccine at a new mass vaccination centre in WiZink sports arena in Madrid, Spain, April 9, 2021. REUTERS/Sergio Perez
ZURICH, April 8 (Reuters) - International drug regulators have said the benefits of using COVID-19 vaccines developed by Johnson & Johnson (JNJ.N) and AstraZeneca (AZN.L) outweigh risks as they investigate reports of extremely rare, but potentially fatal blood clots.
Several EU countries have restricted their use.
Amid concerns that reports of rare side-effects could undermine vaccine confidence, experts have emphasised that clotting risks for both shots remain extremely low and the vaccines are highly effective in preventing COVID-19 deaths and severe disease.
Here's what we know so far:
With both the AstraZeneca and J&J vaccines, the reports involve extremely rare clotting, mainly a type of blood clot called cerebral venous sinus thrombosis (CVST), seen in combination with low blood platelet levels, called thrombocytopenia.
The European Medicines Agency (EMA) said most clots had occurred in the brain and abdomen.
The U.S. Centers for Disease Control (CDC) said the clotting events have been documented in numerous areas of the body, including the femoral vein and artery, internal jugular vein, upper extremity veins and the pulmonary artery.
As of April 20, there had been more than 300 clotting incidents with low platelets reported, out of tens of millions of shots administered. read more
That included 287 cases of clotting - including CVST and splanchnic vein thrombosis (SVT) which is clotting in veins in the abdomen - linked to the AstraZeneca vaccine.
Europe's regulator is now reviewing the first report in the region of a death potentially linked to J&J's vaccine, after a 37-year-old woman in Belgium suffered from a blood clot with low platelets. read more
More than 1.34 million J&J doses have been administered within the EU.
J&J has said that no clear causal relationship has been established between the vaccine and the clots.
It resumed shipping its one-dose vaccine to Europe and the United States in late April with a warning on its label after a brief pause due to U.S. clotting cases. read more
AstraZeneca, whose vaccine packaging also includes a warning label required by regulators, has said it is working to understand individual cases and "possible mechanisms that could explain these extremely rare events".
The CDC has said it has found a "plausible causal association" between J&J's shot and clotting after identifying 28 cases of the side-effects among around 9 million people who had received J&J's vaccine. read more
The U.S. Food and Drug Administration has said the vaccine is safe and effective in preventing COVID-19, while issuing guidance to medical professionals on how to respond, should clots emerge. read more
Europe's drug regulator has also found a possible link between rare clotting and J&J and AstraZeneca shots, but maintained the benefits of getting vaccinated outweighed the risks. read more
It has recommended that anyone who developed blood clots with low blood platelets after receiving the first dose should get an alternative shot for the second dose. read more
The agency has left it up to individual countries to decide how to administer the shots, saying factors may vary including infection rates and whether there are vaccine alternatives to influence local policies.
Britain's Medicines and Healthcare products Regulatory Agency recommended people under 40 get an alternative vaccine to AstraZeneca's citing low levels of COVID-19 infection there and the availability of other vaccines.
Among possible causes being investigated is that the vaccine triggers an unusual antibody response in rare cases. So far, risk factors like age or gender have not been singled out.
Health regulators and scientists are exploring whether the clotting problem may affect the whole class of so-called viral vector vaccines, which the EMA said was possible, while noting differences in the two shots, including the vectors they use to deliver vaccine material.
A group of German researchers said their laboratory research showed the rare clotting events were linked to the cold viruses used to deliver vaccine material to the body. read more
Separate teams of German scientists at Greifswald University and Norwegian scientists have concluded the extremely rare cases of clotting with low platelets are triggered in part by antibodies found in the affected patients who received AstraZeneca's shot.
Reporting by Ludwig Burger in Frankfurt, Matthias Blamont in Paris and John Miller in Zurich Additional reporting by Kate Kelland and Alistair Smout in London and Julie Steenhuysen in Chicago Editing by Josephine Mason and Angus MacSwan
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
Play video on original page
Read Next
Asia Pacific
AstraZeneca scours supply chain for more vaccine doses for Thailand, SE Asia
12:49 AM PDT
Asia Pacific
Malaysia reports record 15,902 new coronavirus cases
12:38 AM PDT
China administered total 1.5249 bln doses of COVID-19 vaccines as of July 23
12:26 AM PDT
Asia Pacific
Factbox: Coronavirus cases at the Tokyo Olympics
12:00 AM PDT

Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals · July 23, 2021 · 8:47 PM PDT
U.S. appeals court lifts CDC cruise ship restrictions in win for Florida
A federal appeals court late on Friday reversed course and let stand a lower court order prohibiting the U.S. Centers for Disease Control and Prevention (CDC) from enforcing coronavirus-related cruise ship rules in Florida.
Healthcare & Pharmaceuticals
AstraZeneca scours supply chain for more vaccine doses for Thailand, SE Asia
12:49 AM PDT
Healthcare & Pharmaceuticals
White House says new Pfizer vaccine order could help if booster shot needed
July 23, 2021
Healthcare & Pharmaceuticals
Vaccinated people make up 75% of recent COVID-19 cases in Singapore, but few fall ill
July 23, 2021
Healthcare & Pharmaceuticals
J&J shot recipients may need a booster; new advice on infected kids
July 23, 2021
About Reuters
About Reuters
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface.
Refinitiv Data Platform
Access to real-time, reference, and non-real time data in the cloud to power your enterprise.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Terms of Use
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved